Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
PurposeTo compare the survival benefit in the adjuvant chemoradiotherapy (CRT) group and chemotherapy (CT) group for stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection.Methods and MaterialsFrom January 2011 to May 2018, 819 patients (CRT group: 215 patients, CT group:...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.916937/full |
| _version_ | 1811224578591031296 |
|---|---|
| author | Jinming Shi Wenzhe Kang Yuan Tang Ning Li Liming Jiang Lin Yang Shulian Wang Yongwen Song Yueping Liu Hui Fang Ningning Lu Shunan Qi Bo Chen Yexiong Li Yantao Tian Jing Jin Jing Jin |
| author_facet | Jinming Shi Wenzhe Kang Yuan Tang Ning Li Liming Jiang Lin Yang Shulian Wang Yongwen Song Yueping Liu Hui Fang Ningning Lu Shunan Qi Bo Chen Yexiong Li Yantao Tian Jing Jin Jing Jin |
| author_sort | Jinming Shi |
| collection | DOAJ |
| description | PurposeTo compare the survival benefit in the adjuvant chemoradiotherapy (CRT) group and chemotherapy (CT) group for stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection.Methods and MaterialsFrom January 2011 to May 2018, 819 patients (CRT group: 215 patients, CT group: 604 patients) diagnosed as pathological stage III after D2/R0 resection were retrospectively collected and the survival and recurrence patterns were analyzed. The baseline characteristics were balanced based on propensity score matching (PSM). The survival benefit was compared between two groups using Kaplan–Meier analysis and Cox regression model.ResultsThe 5-year overall survival (OS) rate in the CRT group was significantly higher than that in the CT group whether before or after the PSM. The multivariate Cox regression analysis identified the significant poor OS in patients with advanced TNM stage (P < 0.001) and patients who did not receive the adjuvant CRT (P = 0.008). For the recurrence patterns, 85 (39.5%) patients in the CRT group and 300 (49.7%) patients in the CT group were diagnosed as recurrence (P = 0.011). The regional recurrence in the CRT group was less than that in the CT group (20.5% vs. 35.1%, P = 0.028).ConclusionFor patients diagnosed as stage III gastric cancer or gastroesophageal junction cancer, the addition of adjuvant chemoradiotherapy will significantly improve the overall survival and regional control. |
| first_indexed | 2024-04-12T08:51:23Z |
| format | Article |
| id | doaj.art-2a364b9361b144248ab2b553862f3146 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T08:51:23Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2a364b9361b144248ab2b553862f31462022-12-22T03:39:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.916937916937Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 ResectionJinming Shi0Wenzhe Kang1Yuan Tang2Ning Li3Liming Jiang4Lin Yang5Shulian Wang6Yongwen Song7Yueping Liu8Hui Fang9Ningning Lu10Shunan Qi11Bo Chen12Yexiong Li13Yantao Tian14Jing Jin15Jing Jin16Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Pancreatic and Gastric Surgery , National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaState Key Laboratory of Molecular Oncology and Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, ChinaState Key Laboratory of Molecular Oncology and Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Pancreatic and Gastric Surgery , National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaPurposeTo compare the survival benefit in the adjuvant chemoradiotherapy (CRT) group and chemotherapy (CT) group for stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection.Methods and MaterialsFrom January 2011 to May 2018, 819 patients (CRT group: 215 patients, CT group: 604 patients) diagnosed as pathological stage III after D2/R0 resection were retrospectively collected and the survival and recurrence patterns were analyzed. The baseline characteristics were balanced based on propensity score matching (PSM). The survival benefit was compared between two groups using Kaplan–Meier analysis and Cox regression model.ResultsThe 5-year overall survival (OS) rate in the CRT group was significantly higher than that in the CT group whether before or after the PSM. The multivariate Cox regression analysis identified the significant poor OS in patients with advanced TNM stage (P < 0.001) and patients who did not receive the adjuvant CRT (P = 0.008). For the recurrence patterns, 85 (39.5%) patients in the CRT group and 300 (49.7%) patients in the CT group were diagnosed as recurrence (P = 0.011). The regional recurrence in the CRT group was less than that in the CT group (20.5% vs. 35.1%, P = 0.028).ConclusionFor patients diagnosed as stage III gastric cancer or gastroesophageal junction cancer, the addition of adjuvant chemoradiotherapy will significantly improve the overall survival and regional control.https://www.frontiersin.org/articles/10.3389/fonc.2022.916937/fulladjuvant chemoradiotherapyadjuvant chemotherapygastroesophageal junction cancergastric cancersurvival analysis |
| spellingShingle | Jinming Shi Wenzhe Kang Yuan Tang Ning Li Liming Jiang Lin Yang Shulian Wang Yongwen Song Yueping Liu Hui Fang Ningning Lu Shunan Qi Bo Chen Yexiong Li Yantao Tian Jing Jin Jing Jin Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection Frontiers in Oncology adjuvant chemoradiotherapy adjuvant chemotherapy gastroesophageal junction cancer gastric cancer survival analysis |
| title | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection |
| title_full | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection |
| title_fullStr | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection |
| title_full_unstemmed | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection |
| title_short | Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection |
| title_sort | adjuvant chemoradiotherapy versus adjuvant chemotherapy for stage iii gastric or gastroesophageal junction cancer after d2 r0 resection |
| topic | adjuvant chemoradiotherapy adjuvant chemotherapy gastroesophageal junction cancer gastric cancer survival analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.916937/full |
| work_keys_str_mv | AT jinmingshi adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT wenzhekang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT yuantang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT ningli adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT limingjiang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT linyang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT shulianwang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT yongwensong adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT yuepingliu adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT huifang adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT ningninglu adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT shunanqi adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT bochen adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT yexiongli adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT yantaotian adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT jingjin adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection AT jingjin adjuvantchemoradiotherapyversusadjuvantchemotherapyforstageiiigastricorgastroesophagealjunctioncancerafterd2r0resection |